Message #24 From:
NewsBot Date: December 19, 2005 07:29:00 AM
EVSC News Endovasc Announces Results from Shareholders' Meeting
MONTGOMERY, Texas--(BUSINESS WIRE)--Dec. 19, 2005--Endovasc, Inc. - (OTCBB: EVSC) a Business Development Company focused on acquiring and investing in innovative drug development in the areas of cardiovascular and metabolic medicine, announces results from the Company's Annual Meeting of Stockholders held on December 16, 2005.
The Company is pleased to report that shareholders reelected Barbara J. Richardson for an additional three-year term, approved McConnell & Jones LLP as the Company's independent registered public accounting firm, approved the amendment to the Company's Articles of Incorporation to increase the number of authorized Common Stock shares, and voted in favor of the Company's 2005 Executive Compensation Plan.
Due to mailing errors by the proxy service, the Company did not receive the votes from a majority of the Series NDC Stock and the meeting was adjourned until January 13, 2006 to provide additional time for the holders of the Series NDC Stock to vote on a proposed amendment to the Certificate of Designations.
"We thank all of our shareholders that have returned their voting instructions and for their overwhelming support of all of management's proposals," said Dr. Diane Dottavio, the Company's Chief Executive Officer. "I encourage the holders of the Series NDC Stock to promptly return their votes approving the last item on the agenda so we can move ahead with our plans for the new year," Dottavio added.
About Endovasc, Inc.
Endovasc, Inc., established in 1996, is a Business Development Company focused on acquiring and investing in innovative drug development in the areas of cardiovascular and metabolic medicine. Endovasc's subsidiaries include: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Nutraceutical Development Corporation which has an agreement in place with an innovative product development company to commercialize its muscle mass enhancing product; and Prostent, a stent coating technology.
For more information about Endovasc, please visit www.endovasc.com.
Safe Harbor Statement
The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release.
